Gene Therapies

With a novel therapy from newborn heart cells, Secretome Therapeutics heads to J.P. Morgan to showcase its progress against intractable heart failure.

With promising survival data and a pivotal Phase 3 trial underway, Imunon's localized immunotherapy could finally change the game for ovarian cancer.

Ultragenyx's stock plummets after its Osteogenesis Imperfecta drug fails to reduce fractures, a major blow for patients and a test of the firm's pipeline.

As its cash runway shortens, Longeveron's novel stem cell therapy gets a major boost with selection for a prestigious Alzheimer's health moonshot.

With a promising schizophrenia drug stalled by FDA requirements and finances tight, Reviva Pharmaceuticals' upcoming presentation is more than just a talk.

Early data shows QurAlis' QRL-101 successfully engaged its intended target in ALS patients, a key step for a novel drug aimed at quelling neuronal storm.

Mirum raises over a quarter-billion dollars to acquire Bluejay Therapeutics, targeting a high-potential liver disease drug and signaling major growth.

A new oral drug, cadisegliatin, enters a major clinical trial in the UAE, aiming to help Type 2 diabetes patients struggling with insulin therapy.

Avantor appoints financial heavyweight Simon Dingemans to its board, a strategic move to accelerate its ambitious turnaround amid market pressures.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

Incyte's Minjuvi, a first-of-its-kind immunotherapy, gains EC approval for follicular lymphoma, offering patients a powerful new chemo-free option.

A Phase 1 trial for Moleculin's WP1066 shows encouraging safety and anti-tumor activity for children with deadly brain tumors like DIPG.

New data shows Vyriad's VV169 eliminated myeloma in mice without severe toxicity, signaling a potential shift to safer, scalable 'off-the-shelf' CAR T.

Pfizer projects lower 2026 earnings as COVID sales wane and patents expire, shifting focus to a multi-billion dollar R&D push for future growth.

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.

Anixa Biosciences now fully controls its breast cancer vaccine after promising Phase 1 data. What does this strategic move mean for investors and medicine?

With FDA alignment for its pivotal Phase 3 trial, Oncolytics Biotech is poised to bring the first immunotherapy to the challenging pancreatic cancer landscape.

A positive EU opinion for Sobi's Aspaveli could bring the first-ever targeted treatment for two rare kidney diseases, shaking up a market desperate for innovation.

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

Tenaya Therapeutics unveils promising interim data for its ARVC gene therapy, TN-401, hinting at a potential cure and igniting investor interest.